It is obvious that EGCG possess the ability to slow down the progression of lymphocytic leukemia. Clinical effectiveness of a substance is not very high, however statistically significant. The results suggest that EGCG can be successfully used in combination with other drugs at the early stages of lymphocytic leukemia.

The study involved 42 patients with chronic lymphocytic leukemia. All patients were at early stage of the disease. After the application of epigallocatechin gallate, the amount of leukemia cells are reduced by 20%. Nearly 70% of patients noticed decreasing the size of lymph nodes by 50%.

Apparently, the treatment with epigallocatechin gallate can not replace chemotherapy. However, the obtained results are very encouraging. Scientists plan to continue research to identify the maximum potential of the polyphenols in green tea.

The results will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Currently, a lot of people suffer from moderate to severe chronic pain caused by low-back pain, neck pain and trauma. In fact, physicians frequently try many types of narcotic analgetics (pain killers) before finding an appropriate dose regimen that will provide expected analgesic effect. The active ingredient of Exalgo – hydromorphone Hcl has been used in clinical trials since 1930th and soon will be available in the form of extended release tablets. This will significantly happen to choose the appropriate dose for a short period of time and avoid multiply combinations of pain killers.
Exalgo is taken once daily to control and relieve severe or moderate pain in those patients with tolerance to opioids which require all day long opioid analgesic effect.
Exalgo possesses a specific osmotic delivery system, OROS ® Push-Pull, which allows ещ release hydromorphone at a constant controlled level.

It is expected that Exalgo will be launched on pharmaceutical market in the first half of 2010 and also will include a special risk management program (REMS). This program involves the creation of a special booklet for patients and medical staff training plan for safe use of the drug.